The POSITION20 trial which explored high‐dose osimertinib in patients with EGFR exon 20 mutation‐positive advanced NSCLC, showed modest antitumor activity with a confirmed ORR of 28%, PFS of 6.8 months, and acceptable toxicity [15]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.